Intravenous aminophylline dosage. Use of serum theophylline measurement for guidance. 1976

M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty

A practical method for monitoring serum theophylline concentrations has been used to investigate intravenous aminophylline dosage requirements. Initial serum theophylline concentrations were found to vary widely and correlate poorly with drug history. Aminophylline loading doses determined from these values more frequently resulted in drug concentrations in the therapeutic range (10 mug to 20 mug/ml) than when therapy was given without knowledge of serum theophylline concentrations. Continuous intravenous aminophylline therapy administered in a standardized dosage (0.9 mg/kg/hr in adults and 1.0 mg/kg/hr in children) produced variable and often excessive serum concentrations. This resulted from variable drug clearance rates, which in adults averaged 0.64 +/- 0.38 ml/kg/min (mean +/- SD), only half that previously reported. These observations suggest that it is not possible to achieve optimal therapeutic aminophylline dosage without monitoring serum theophylline concentrations.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D012131 Respiratory Insufficiency Failure to adequately provide oxygen to cells of the body and to remove excess carbon dioxide from them. (Stedman, 25th ed) Acute Hypercapnic Respiratory Failure,Acute Hypoxemic Respiratory Failure,Hypercapnic Acute Respiratory Failure,Hypercapnic Respiratory Failure,Hypoxemic Acute Respiratory Failure,Hypoxemic Respiratory Failure,Respiratory Depression,Respiratory Failure,Ventilatory Depression,Depressions, Ventilatory,Failure, Hypercapnic Respiratory,Failure, Hypoxemic Respiratory,Failure, Respiratory,Hypercapnic Respiratory Failures,Hypoxemic Respiratory Failures,Respiratory Failure, Hypercapnic,Respiratory Failure, Hypoxemic,Respiratory Failures
D001986 Bronchial Spasm Spasmodic contraction of the smooth muscle of the bronchi. Bronchospasm,Bronchial Spasms,Bronchospasms,Spasm, Bronchial,Spasms, Bronchial
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas

Related Publications

M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
July 1980, American journal of hospital pharmacy,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
December 1982, Annals of allergy,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
March 1984, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
May 1985, Journal of pharmaceutical sciences,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
April 1982, Drug intelligence & clinical pharmacy,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
March 1984, British medical journal (Clinical research ed.),
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
March 1986, Medicina clinica,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
November 1980, European journal of clinical pharmacology,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
October 1984, British journal of clinical pharmacology,
M W Weinberger, and R A Matthay, and E J Ginchansky, and C A Chidsey, and T L Petty
July 1978, The American review of respiratory disease,
Copied contents to your clipboard!